IP waiver won’t solve vaccine problems, warn experts

A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization (WTO) failing to reach consensus.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

COVID-19 IP waiver faces uncertain future

31 March 2022 The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa.

Big Pharma

US, EU, India and South Africa reach COVID waiver ‘compromise’

16 March 2022 The US, EU, India and South Africa have reached an undisclosed agreement related to the stonewalled COVID-19 vaccine IP waiver.

Africa

MSF urges South Africa to open access to COVID-19 generics

10 February 2022 Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

IP waiver won’t solve vaccine problems, warn experts

More on this story

Editor's picks

Editor's picks

More features